Inventor · disambiguated record
Daniel T. Dransfield
Also filed as: DRANSFIELD DANIEL T
25 granted patents·17 pending applications·313 citations·filing 2003–2022
96Inventor score
Top patents by PatentIndex Score
42 records- 0197US8044175B2Peptides that specifically bind HGF receptor (CMET) and uses thereofDYAX CORP·Filed 2008·Granted Oct 25, 2011·44 cites·4 claims
- 0296US7910088B2Multivalent constructs for therapeutic and diagnostic applicationsBRACCO SUISSE SA·Filed 2007·Granted Mar 22, 2011·24 cites·33 claims
- 0395US7854919B2Multivalent constructs for therapeutic and diagnostic applicationsBRACCO SUISSE SA·Filed 2007·Granted Dec 21, 2010·20 cites·50 claims
- 0495US7485297B2Method of inhibition of vascular development using an antibodyDYAX CORP·Filed 2005·Granted Feb 3, 2009·35 cites·30 claims
- 0594US9056138B2Multivalent constructs for therapeutic and diagnostic applicationsBRACCO SUISSE SA·Filed 2013·Granted Jun 16, 2015·11 cites·22 claims
- 0694US7261876B2Multivalent constructs for therapeutic and diagnostic applicationsDYAX CORP·Filed 2003·Granted Aug 28, 2007·33 cites·33 claims
- 0794US7211240B2Multivalent constructs for therapeutic and diagnostic applicationsDYAX CORP·Filed 2003·Granted May 1, 2007·52 cites·67 claims
- 0892US8663603B2Multivalent constructs for therapeutic and diagnostic applicationsARBOGAST CHRISTOPHE·Filed 2010·Granted Mar 4, 2014·12 cites·23 claims
- 0991US8632753B2Multivalent constructs for therapeutic and diagnostic applicationsFAN HONG·Filed 2010·Granted Jan 21, 2014·12 cites·21 claims
- 1091US7745587B2Antibodies that bind MMP-14DYAX CORP·Filed 2006·Granted Jun 29, 2010·19 cites·32 claims
- 1188US8642010B2KDR and VEGF/KDR binding peptides and their use in diagnosis and therapySATO AARON K·Filed 2009·Granted Feb 4, 2014·9 cites·42 claims
- 1287US8147836B2Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteinsWOOD CLIVE R·Filed 2008·Granted Apr 3, 2012·11 cites·16 claims
- 1386US7871610B2Antibodies to Tie1 ectodomainDYAX CORP·Filed 2005·Granted Jan 18, 2011·9 cites·29 claims
- 1485US9000124B2Peptides that specifically bind HGF receptor (cMet) and uses thereofDRANSFIELD DANIEL T·Filed 2011·Granted Apr 7, 2015·8 cites·12 claims
- 1579US8106168B2Metalloproteinase binding proteinsDEVY LAETITIA·Filed 2010·Granted Jan 31, 2012·4 cites·27 claims
- 1676US8183008B2Evaluating MMP expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancerWOOD CLIVE R·Filed 2008·Granted May 22, 2012·4 cites·19 claims
- 1774US8501181B2Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteinsWOOD CLIVE R·Filed 2011·Granted Aug 6, 2013·2 cites·16 claims
- 1870US9629934B2KDR and VEGF/KDR binding peptides and their use in diagnosis and therapyDYAX CORP·Filed 2013·Granted Apr 25, 2017·0 cites·15 claims
- 1970US2010260672A1Peptides that specifically bind hgf receptor (cmet) and uses thereofDYAX CORP·Filed 2009·Application pending·0 cites
- 2069US9446155B2KDR and VEGF/KDR binding peptides and their use in diagnosis and therapyDYAX CORP·Filed 2013·Granted Sep 20, 2016·0 cites·20 claims
- 2169US9051377B2Method for treating breast cancer using antibody binding to MMP-14DEVY LAETITIA·Filed 2011·Granted Jun 9, 2015·1 cites·18 claims
- 2269US2024000962A1Glycan-Interacting Compounds and Methods of UseSEAGEN INC·Filed 2022·Application pending·0 cites
- 2368US7514534B2Metalloproteinase-binding proteinsDYAX CORP·Filed 2004·Granted Apr 7, 2009·3 cites·13 claims
- 2465US2023001007A1Glycan-Interacting Compounds and Methods of UseSEAGEN INC·Filed 2022·Application pending·0 cites
- 2563US2005100963A1KDR and VEGF/KDR binding peptides and their use in diagnosis and therapyBRACCO INT BV·Filed 2003·Application pending·0 cites
- 2662US2015374843A1Multivalent constructs for therapeutic and diagnostic applicationsBRACCO SUISSE SA·Filed 2015·Application pending·0 cites
- 2760US2010196361A1Method of inhibition of vascular development using an antibodyDYAX CORP·Filed 2008·Application pending·0 cites
- 2859US9845340B2Peptides that specifically bind HGF receptor (cMet) and uses thereofDYAX CORP·Filed 2015·Granted Dec 19, 2017·0 cites·14 claims
- 2959US2010291001A1Metalloproteinase-binding proteinsDYAX CORP·Filed 2008·Application pending·0 cites
- 3059US2005214859A1Peptides that specifically bind HGF receptor (cMet) and uses thereofDYAX CORP·Filed 2004·Application pending·0 cites
- 3158US11253609B2Glycan-interacting compounds and methods of useSEAGEN INC·Filed 2018·Granted Feb 22, 2022·0 cites·13 claims
- 3255US2024299352A1Combination therapies with setd2 inhibitorsEPIZYME INC·Filed 2022·Application pending·0 cites
- 3355US2012039802A1Peptides that specifically bind hgf receptor (cmet) and uses thereofDRANSFIELD DANIEL T·Filed 2011·Application pending·0 cites
- 3453US2013244890A1Evaluating mmp expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancerWOOD CLIVE R·Filed 2012·Application pending·0 cites
- 3552US10314909B2Combination therapy comprising an MMP-14 binding proteinDYAX CORP·Filed 2012·Granted Jun 11, 2019·0 cites·35 claims
- 3649US2008213253A1Combination therapy for the treatment of cancerDYAX CORP·Filed 2008·Application pending·0 cites
- 3747US2008160019A1Sequential combination therapyDYAX CORP·Filed 2007·Application pending·0 cites
- 3846US2011165145A1Igf-ii/igf-iie binding proteinsDRANSFIELD DANIEL T·Filed 2009·Application pending·0 cites
- 3944US2005250700A1KDR and VEGF/KDR binding peptidesSATO AARON K·Filed 2004·Application pending·0 cites
- 4044US2011059105A1Tie complex binding proteinsDYAX CORP·Filed 2010·Application pending·0 cites
- 4142US9949981B2Compositions and methods for treating proliferation disordersARQULE INC·Filed 2015·Granted Apr 24, 2018·0 cites·20 claims
- 4240US2014199324A1Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancerDRANSFIELD DANIEL T·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Daniel T. Dransfield files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →